DGAP-News

Neovacs S.A.: Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship - Seite 3

proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the fields
of auto-immune diseases, oncology and allergies. The goal of the Kinoid
approach is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX-V: KLH) is a leader in
sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important
immune-stimulating protein used in wide-ranging therapeutic and diagnostic
markets. KLH is both an active pharmaceutical ingredient (API) in many new
immunotherapies (targeting cancer, immune disorders, Alzheimer's, and
inflammatory diseases) as well as a finished product for measuring immune
status. Stellar Biotechnologies is unique in its proprietary methods,
facilities, and KLH technology. It is committed to meeting the growing
demand for commercial-scale supplies of GMP grade KLH, ensuring
environmentally sound KLH production, and developing KLH-based active
immunotherapies.

Visit www.stellarbiotech.com and the Stellar KLH knowledge base
www.klhsite.org.

Stellar Biotechnologies Company Contact:

Mark A. McPartland
Vice President of Corporate Development and Communications
[phone] ext. 103
[e-mail]
www.stellarbiotech.com

Neovacs Company Contacts:

NEOVACS - Investor Relations
Nathalie Trépo
[phone]
[e-mail]

Investor Relations / Financial Communications - NewCap
Valentine Brouchot / Pierre Laurent
[phone]
[e-mail]

Investor Relations / Financial Communications Germany - MC Services
Raimund Gabriel
[phone]
[e-mail]

Press / U.S. Inquiries - The Ruth Group
Melanie Sollid-Penton
1.646.536.7023
[e-mail]



Forward Looking Statements

This press release may contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by the use of words such as